Attached files
file | filename |
---|---|
EX-31.2 - VistaGen Therapeutics, Inc. | ex31-2.htm |
EX-31.1 - VistaGen Therapeutics, Inc. | ex31-1.htm |
EX-10.2 - VistaGen Therapeutics, Inc. | ex10-2.htm |
EX-10.1 - VistaGen Therapeutics, Inc. | ex10-1.htm |
10-Q - FORM 10-Q - VistaGen Therapeutics, Inc. | vtgn10q_sep302016.htm |
EXHIBIT 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the Quarterly Report on Form 10-Q of VistaGen
Therapeutics, Inc. (the “Company”) for the quarter ended
September 30, 2016 as filed with the Securities and Exchange
Commission on the date hereof (the “Report”), Shawn K. Singh, JD, the
Company’s Principal Executive Officer, and Jerrold D. Dotson,
the Company’s Principal Financial Officer, certify, pursuant
to 18 U.S.C. §1350, as adopted pursuant to §906 of the
Sarbanes-Oxley Act of 2002, that to the best of their
knowledge:
1.
The Report fully
complies with the requirement of Section 13(a) or Section 15 (d) of
the Securities Exchange Act of 1934, and
2.
The information
contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the
Company.
November
14, 2016
/s/ Shawn K. Singh
Shawn
K. Singh
Principal
Executive Officer
/s/ Jerrold D. Dotson
Jerrold
D. Dotson
Principal
Financial Officer